91
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
Condition(s):Hemophilia ALast Updated:April 14, 2022Recruiting
Factor VIII: 881 Clinical Trials, Page 10 of 89
Hide Studies Not Open or Pending
92
Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
Condition(s):Hemophilia ALast Updated:April 22, 2008Completed
93
Kogenate FS Regulatory Post-Marketing Surveillance
Condition(s):Hemophilia ALast Updated:August 21, 2014Completed
94
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Condition(s):Hemophilia ALast Updated:January 18, 2023Recruiting
95
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition(s):Acquired Hemophilia ALast Updated:August 5, 2021Completed
96
BAX 855 Dose-Escalation Safety Study
Condition(s):Hemophilia ALast Updated:May 5, 2021Completed
97
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
Condition(s):Hemophilia ALast Updated:April 27, 2021Completed
98
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Condition(s):Hemophilia ALast Updated:May 24, 2021Completed
99
Extension at 10 Years of the: “Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.”
Condition(s):Hemophilia ALast Updated:November 18, 2020Completed
100
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients – A Continuation of Clinical Study 069901
Condition(s):Hemophilia ALast Updated:August 24, 2021Completed